Antisense Oligonucleotides Modulate Globin Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for conditions like beta-thalassemia and sickle cell disease related to abnormal globin gene expression lack effective solutions for modulating globin gene expression and function, leading to inadequate treatment outcomes.
Innovation Solution
Development of antisense oligonucleotides that bind to sense and antisense globin polynucleotides, specifically using modified nucleobases and bonds such as phosphorothioate, methylphosphonate, and locked nucleic acid molecules, administered via various routes, potentially encapsulated in liposomes, to modulate globin gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for beta-thalassemia and sickle cell disease, then treatment is provided, but effective modulation of globin gene expression is not achieved
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to specific globin polynucleotide sequences to modulate gene expression. These oligonucleotides act as mediators between the therapeutic goal and the target gene, enabling precise control of globin expression without directly altering the gene itself. The modified nucleobases and bonds enhance the binding affinity and stability of this intermediary interaction.
Solution Approach 2:
The patent employs chemical modifications to the oligonucleotide structure (modified nucleobases such as phosphorothioate, methylphosphonate, and locked nucleic acid molecules) to change the physical and chemical parameters of the therapeutic agent. These parameter changes improve nuclease resistance, cellular uptake, and binding affinity, thereby enhancing treatment effectiveness while maintaining gene expression modulation capability.
2Reliability
If antisense oligonucleotides with modified nucleobases are used, then fetal hemoglobin production is increased, but treatment complexity increases
Solution Approach 1:
The patent applies modifications locally to specific positions within the oligonucleotide sequence rather than uniformly across the entire molecule. Different regions of the oligonucleotide have different properties: some regions contain modified nucleobases for enhanced stability and binding, while other regions maintain natural sequences for optimal gene targeting. This local differentiation achieves high fetal hemoglobin production while managing structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides effectively increase fetal hemoglobin production, reducing painful episodes in sickle cell disease and addressing abnormal globin gene expression, offering a therapeutic approach for beta-thalassemia and related disorders.
Implementation Method 1
DNA-RNA and RNA-RNA hybridization are important to many aspects of nucleic acid function including DNA replication, transcription, and translation. Hybridization is also central to a variety of technologies that either detect a particular nucleic acid or alter its expression.
Implementation Method 2
Antisense DNA has the added feature that DNA-RNA hybrids serve as a substrate for digestion by ribonuclease H, an activity that is present in most cell types.
Data Source
Figure 1
AI summary
Antisense compounds modulate expression and/or function of globin genes. Methods for treating diseases associated with globins comprise administering one or more antisense compounds to patients.